Evgenia Gourgari, Gitanjali Srivastava, Aaron S. Kelly, Donna Mojdami, Dachuang Cao, Madhumita A. Murphy, Chrisanthi A. Karanikas, Clare J. Lee
{"title":"早发性肥胖和替西肽治疗：一项对SURMOUNT临床试验的事后分析。","authors":"Evgenia Gourgari, Gitanjali Srivastava, Aaron S. Kelly, Donna Mojdami, Dachuang Cao, Madhumita A. Murphy, Chrisanthi A. Karanikas, Clare J. Lee","doi":"10.1002/oby.24348","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>People with early-onset obesity (diagnosed at age < 25 years) may present with more cardiometabolic abnormalities and obesity-related complications. This post hoc analysis assessed baseline characteristics and body weight (BW) changes with tirzepatide in people with early- versus later-onset obesity.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Participants (<i>N</i> = 3782) from SURMOUNT-1, SURMOUNT-3, and SURMOUNT-4 randomized to tirzepatide or placebo were included. Baseline characteristics and changes in BW and cardiometabolic risk factors at 72/88 weeks were assessed.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>In SURMOUNT-1, participants with early- versus later-onset obesity had longer mean obesity duration (20 ± 12 vs. 11 ± 8 years), higher BMI (40 ± 7 vs. 37 ± 6 kg/m<sup>2</sup>) and waist circumference (WC, 118 ± 16 vs. 112 ± 14 cm), and lower HbA1c (5.48% ± 0.4% vs. 5.60% ± 0.4%), triglycerides (median 120 vs. 130 mg/dL), and systolic blood pressure (SBP; 121 ± 13 vs. 125 ± 13 mmHg) at baseline (all <i>p</i> ≤ 0.004). At 72 weeks, improvements with tirzepatide in BW (−23% vs. −22%), WC (−22 vs. −19 cm), HbA1c (−0.51% vs. −0.52%), triglycerides (−32% vs. −31%), and SBP (−8 vs. −8 mmHg) were similar between subgroups. Similar improvements were observed in SURMOUNT-3 and SURMOUNT-4.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>In this post hoc analysis, participants with early- versus later-onset obesity exhibited a mixed profile of metabolic health at baseline, including a higher degree of central adiposity and lower HbA1c and SBP. Improvements in BW and cardiometabolic markers with tirzepatide were similar between subgroups.</p>\n </section>\n \n <section>\n \n <h3> Trial Registration</h3>\n \n <p>\n ClinicalTrials.gov identifiers: NCT04184622, NCT04657016, NCT04660643</p>\n \n <div>\n \n <figure>\n <div><picture>\n <source></source></picture><p></p>\n </div>\n </figure>\n </div>\n </section>\n </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"33 9","pages":"1668-1679"},"PeriodicalIF":4.7000,"publicationDate":"2025-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.24348","citationCount":"0","resultStr":"{\"title\":\"Early-Onset Obesity and Tirzepatide Treatment: A Post Hoc Analysis of the SURMOUNT Clinical Trials\",\"authors\":\"Evgenia Gourgari, Gitanjali Srivastava, Aaron S. Kelly, Donna Mojdami, Dachuang Cao, Madhumita A. Murphy, Chrisanthi A. Karanikas, Clare J. Lee\",\"doi\":\"10.1002/oby.24348\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Objective</h3>\\n \\n <p>People with early-onset obesity (diagnosed at age < 25 years) may present with more cardiometabolic abnormalities and obesity-related complications. This post hoc analysis assessed baseline characteristics and body weight (BW) changes with tirzepatide in people with early- versus later-onset obesity.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Participants (<i>N</i> = 3782) from SURMOUNT-1, SURMOUNT-3, and SURMOUNT-4 randomized to tirzepatide or placebo were included. Baseline characteristics and changes in BW and cardiometabolic risk factors at 72/88 weeks were assessed.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>In SURMOUNT-1, participants with early- versus later-onset obesity had longer mean obesity duration (20 ± 12 vs. 11 ± 8 years), higher BMI (40 ± 7 vs. 37 ± 6 kg/m<sup>2</sup>) and waist circumference (WC, 118 ± 16 vs. 112 ± 14 cm), and lower HbA1c (5.48% ± 0.4% vs. 5.60% ± 0.4%), triglycerides (median 120 vs. 130 mg/dL), and systolic blood pressure (SBP; 121 ± 13 vs. 125 ± 13 mmHg) at baseline (all <i>p</i> ≤ 0.004). At 72 weeks, improvements with tirzepatide in BW (−23% vs. −22%), WC (−22 vs. −19 cm), HbA1c (−0.51% vs. −0.52%), triglycerides (−32% vs. −31%), and SBP (−8 vs. −8 mmHg) were similar between subgroups. Similar improvements were observed in SURMOUNT-3 and SURMOUNT-4.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>In this post hoc analysis, participants with early- versus later-onset obesity exhibited a mixed profile of metabolic health at baseline, including a higher degree of central adiposity and lower HbA1c and SBP. Improvements in BW and cardiometabolic markers with tirzepatide were similar between subgroups.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Trial Registration</h3>\\n \\n <p>\\n ClinicalTrials.gov identifiers: NCT04184622, NCT04657016, NCT04660643</p>\\n \\n <div>\\n \\n <figure>\\n <div><picture>\\n <source></source></picture><p></p>\\n </div>\\n </figure>\\n </div>\\n </section>\\n </div>\",\"PeriodicalId\":215,\"journal\":{\"name\":\"Obesity\",\"volume\":\"33 9\",\"pages\":\"1668-1679\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2025-07-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.24348\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Obesity\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/oby.24348\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/oby.24348","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
摘要
目的：早发性肥胖患者（年龄诊断）方法：纳入来自SURMOUNT-1、SURMOUNT-3和SURMOUNT-4随机分配至替西帕肽或安慰剂组的参与者（N = 3782）。在72/88周时评估基线特征和体重和心脏代谢危险因素的变化。结果：在SURMOUNT-1中，早发性肥胖与晚发性肥胖的参与者平均肥胖持续时间更长（20±12年vs 11±8年），BMI（40±7 vs 37±6 kg/m2）和腰围（WC, 118±16 vs 112±14 cm）更高，HbA1c（5.48%±0.4% vs 5.60%±0.4%）、甘油三酯（中位数120 vs 130 mg/dL）和收缩压(SBP；121±13对125±13 mmHg)（均p≤0.004）。在72周时，替西帕肽对BW （-23% vs. -22%）、WC （-22 vs. -19 cm）、HbA1c （-0.51% vs. -0.52%）、甘油三酯（-32% vs. -31%）和收缩压（-8 vs. -8 mmHg）的改善在亚组之间相似。在SURMOUNT-3和SURMOUNT-4中也观察到类似的改善。结论：在这项事后分析中，早发性肥胖与晚发性肥胖的参与者在基线时表现出混合的代谢健康状况，包括较高程度的中枢性肥胖和较低的HbA1c和收缩压。替西肽对体重和心脏代谢指标的改善在亚组之间相似。试验注册：ClinicalTrials.gov标识符：NCT04184622、NCT04657016、NCT04660643。
Early-Onset Obesity and Tirzepatide Treatment: A Post Hoc Analysis of the SURMOUNT Clinical Trials
Objective
People with early-onset obesity (diagnosed at age < 25 years) may present with more cardiometabolic abnormalities and obesity-related complications. This post hoc analysis assessed baseline characteristics and body weight (BW) changes with tirzepatide in people with early- versus later-onset obesity.
Methods
Participants (N = 3782) from SURMOUNT-1, SURMOUNT-3, and SURMOUNT-4 randomized to tirzepatide or placebo were included. Baseline characteristics and changes in BW and cardiometabolic risk factors at 72/88 weeks were assessed.
Results
In SURMOUNT-1, participants with early- versus later-onset obesity had longer mean obesity duration (20 ± 12 vs. 11 ± 8 years), higher BMI (40 ± 7 vs. 37 ± 6 kg/m2) and waist circumference (WC, 118 ± 16 vs. 112 ± 14 cm), and lower HbA1c (5.48% ± 0.4% vs. 5.60% ± 0.4%), triglycerides (median 120 vs. 130 mg/dL), and systolic blood pressure (SBP; 121 ± 13 vs. 125 ± 13 mmHg) at baseline (all p ≤ 0.004). At 72 weeks, improvements with tirzepatide in BW (−23% vs. −22%), WC (−22 vs. −19 cm), HbA1c (−0.51% vs. −0.52%), triglycerides (−32% vs. −31%), and SBP (−8 vs. −8 mmHg) were similar between subgroups. Similar improvements were observed in SURMOUNT-3 and SURMOUNT-4.
Conclusions
In this post hoc analysis, participants with early- versus later-onset obesity exhibited a mixed profile of metabolic health at baseline, including a higher degree of central adiposity and lower HbA1c and SBP. Improvements in BW and cardiometabolic markers with tirzepatide were similar between subgroups.
期刊介绍：
Obesity is the official journal of The Obesity Society and is the premier source of information for increasing knowledge, fostering translational research from basic to population science, and promoting better treatment for people with obesity. Obesity publishes important peer-reviewed research and cutting-edge reviews, commentaries, and public health and medical developments.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
